Glucose, A1C, kidney markers, electrolytes, liver-related tests, lipids, and selected nutritional biomarkers can provide objective information about treatment response and possible complications
The synergistic effect of activating all three receptors simultaneously promotes significant weight loss and better metabolic control than other existing GLP-1 receptor agonists, such as semaglutide (Wegovy and Ozempic), liraglutide, dulaglutide, and dual-agonists like tirzepatide (Mounjaro and Zepbound)
Understanding individual genetic predispositions supports precision medicinematching medication choice to biology rather than trial-and-error prescribing
Keep on reading below
Join WeightWatchers Clinic and get help and advice on weight-loss medication
Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism
